Файл: Научноквалификационная работа проблема организации скрининга диабетической ретинопатии.doc
ВУЗ: Не указан
Категория: Не указан
Дисциплина: Не указана
Добавлен: 23.11.2023
Просмотров: 99
Скачиваний: 2
ВНИМАНИЕ! Если данный файл нарушает Ваши авторские права, то обязательно сообщите нам.
Browning D.J., Stewart M.W., Lee C. Diabetic macular edema: Evidence-based management. // Indian J Ophthalmol. 2018; 66(12): 1736-1750.
Cardoso C.R. Predictors of Development and Progression of Retinopathy in Patients with Type 2 Diabetes: Importance of Blood Pressure Parameters / C.R. Cardoso, N.C. Leite, E. Dib, G.F. Salles // Sci Rep. – 2017. – Vol. 7, № 1. – Р. 4867.
Cennamo G., Vecchio E.C., Finelli M., Velotti N., de Crecchio G. Evaluation of ischemic diabetic maculopathy with Fourier-domain optical coherence tomography and microperimetry. // Canadian Journal of Ophthalmology / Journal Canadien d’Ophtalmologie [Internet]. Elsevier BV. 2015;50(1):44-48.
Chatziralli I. Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus / I. Chatziralli, T.N. Sergentanis, R. Crosby-Nwaobi, K. Winkley, H. Eleftheriadis, K. Ismail, S.A. Amiel, S. Sivaprasad // Invest Ophthalmol Vis Sci. – 2017. – Vol. 58, № 6. – Р. 99-105.
Chawla R., Nair S., Venkatesh P., Garg S., Mittal K. Bilateral disc drusen in a diabetic patient simulating diabetic papillopathy as a cause of disc edema. // Indian J Ophthalmol. 2017; 65(10): 10511053.
Chen C.F., Liou S.W., Wu H.H., Lin C.H., Huang L.S., Woung L.C. [et al.] Regulatory SNPs alter the gene expression of diabetic retinopathy associated secretary factors. // Int J Med Sci. 2016; 13(9):717-723.
Cheung N.I., Mitchell P., Wong T.Y. Diabetic retinopathy. // Lancet. 2010;376(9735):124-136.
Chieh J.J., Roth D.B., Liu M., Belmont J., Nelson M., Regillo C., Martidis A. Intravitreal triamcinolone acetonide for diabetic macular edema // Retina. 2015. Vol. 25. P. 828–834.
Cho H, Sobrin L. Genetics of diabetic retinopathy. // Curr Diab Rep. 2014 Aug;14(8):515.
Choi S.H., Ruggiero D., Sorice R., Song C., Nutile T., Smith A.V. [et al.] Six novel loci associated with circulating VEGF levels identified by a meta-analysis of genome-wide association studies. // PloS Genet. 2016; 12(2): e1005874.
Chopra R. Lipoprotein (a) as a risk factor for diabetic retinopathy in patients with type 2 diabetes mellitus. / R. Chopra [et al.] // Indian J. Ophthalmol. – 2007. – V. 55, № 3. – Р. 195-198.
Csősz E., Boross P., Csutak A., Berta A., Tóth F., Póliska S. [et al.] Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. // J. Proteomics. 2012; 75(7): 2196-2204.
Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal diabetes register, status. 2017 // Diabetes mellitus. 2018. Vol. 21, no. 3. P. 144–159.
Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. // Curr Diab Rep. 2012;12(4):346-54.
Duh E.J., Sun J.K., Stitt A.W. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. // JCI Insight. 2017; 2(14): e93751.
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs an extension of the modified Airlie House classification. ETDRS report № 10 // Ophthalmology. 1991. Vol. 98. P. 786–806.
El-Asrar A.M. Role of inflammation in the pathogenesis of diabetic retinopathy. // Middle East Afr J Ophthalmol. 2012; 19(1): 70-74.
Esteva A., Chou K., Yeung S. Deep learning-enabled medical computer vision // NPJ digital medicine. 2021. Vol. 4, no. 1. P. 5.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). // JAMA. 2001;285(19):2486-2497.
Fullard R.J., Snyder C. Protein levels in nonstimulated and stimulated tears of normal human subjects. // Invest Ophthalmol Vis Sci. 1990; 31: 1119-1126.
Fullard R.J., Tucker D.L. Changes in human tear protein levels with progressively increasing stimulus. // Investig Ophthalmol Vis Sci. 1991; 32: 2290-2301.
Gaddam S., Periasamy R., Gangaraju R. Adult Stem Cell Therapeutics in Diabetic Retinopath // Int J Mol Sci. 2019. Vol. 20 (19). P. 4876.
Galicia-Garcia U., Benito-Vicente A., Jebari S., Larrea-Sebal A., Siddiqi H., Uribe K.B. [et al.] Pathophysiology of type 2 diabetes mellitus. // Int J Mol Sci. 2020; 21(17): 6275.
Garg S., Davis R.M. Diabetic retinopathy screening update. // Clinical Diabetes Fall. 2009; 27(4): 140-145.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and Management of the Metabolic Syndrome. // Circulation. 2005;112(17):2735-2752.
Gui F., You Z., Fu S., Wu H., Zhang Y. Endothelial dysfunction in diabetic retinopathy. // Front Endocrinol. 2020; 11: 591.
Guo L., Jiang F., Tang Y-T., Si M-Y., Jiao X-Y. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease. // Diabetes Technol Ther. 2014; 16(4): 224-234.
Ha J.M., Jin S.Y., Lee H.S., Shin H.K., Lee D.H., Song S.H. [et al.] Regulation of retinal angiogenesis by endothelial nitric oxide synthase signaling pathway. // Korean J Physiol Pharmacol. 2016; 20(5): 533-538.
Haeringen van N.J. Clinical biochemistry of tears // Surv. Оphthal. 1981. V. 26, N 2. P. 84–96.
Hagan S., Martin E., Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicine. // EPMA J. 2016; 7(1): 15.
Hallman DM, Huber JC Jr, Gonzalez VH, et al. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. // Diabetes Care. 2005 May;28(5):1163-1168.
Hampton B., Schwartz S., Brantley M.A. Jr, Flynn H.W. Jr. Update on genetics and diabetic retinopathy. // Clin Ophthalmol. 2015; 9: 2175-2193.
Herber S., Grus F.H., Sabuncuo P., Augustin A.J. Two-dimensional analysis of tear protein patterns of diabetic patients. // Electrophoresis. 2001; 22(9): 1838-1844.
Hietala K, Forsblom C, Summanen P, et al. Heritability of proliferative diabetic retinopathy. // Diabetes. 2008 Aug;57(8):2176-2180.
Hordern M.D. Exercise prescription for patients with type 2 diabetes and pre-diabetes: A position statement from Exercise and Sport Science Australia. / M.D. Hordern [et al.] // J. Sci. Med. Sport. – 2012. – V. 15. – P. 25-31.
Hu L., Gong C., Chen X., Zhou H., Yan J., Hong W. Associations between vascular endothelial growth factor gene polymorphisms and different types of diabetic retinopathy susceptibility: A systematic review and meta-analysis. // J Diabetes Res. 2021; 2021: 7059139.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. // Diabetes Care. 2015;1(38):140-149.
Iwase T., Mikoshiba Y., Ra E., Yamamoto K., Ueno Y., Terasaki H. Evaluation of blood flow on optic nerve head after pattern scan and conventional laser panretinal photocoagulation // Medicine (Baltimore). 2019. Vol. 98 (24). P. e16062.
Jampo L.M. Classifications of diabetic macular edema. // Eur J Ophthalmol. 2020; 30(1): 6-7.
Jonas JB, Xu L, Wang YX. The Beijing Eye Study. // Acta Ophthalmol. 2009; 87(3): 247-261.
Joshi M.S., Berger P.J., Kaye D.M., Pearson J.T., Bauer J.A., Ritchie R.H. Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction. // Clin Exp Pharmacol Physiol. 2013; 40(4): 253-261.
Kawasaki R. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study / R. Kawasaki, S. Kitano, Y. Sato [et al.] // Diabetol Int. – 2018. – Vol. 10, № 1. – P. 3-11.
Kempen JH, O’Colmain BJ, Leske MC, et al. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathyamong adults in the United States. // Arch Ophthalmol. 2004;122:552–563.
Khairallah M., Zeghidi H., Ladjimi A., Yahia S. B., Attia S., Zaouali S., Messaoud R. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates // Retina. 2015. Vol. 25. P. 835–839.
Kiziltoprak H., Tekin K., Inanc M., Goker Y.S. Cataract in diabetes mellitus // World J. Diabetes. 2019. Vol. 10. P. 140-153.
Klein R, Klein BE, Moss SE, etal. The Wisconsin epidemiologicstudy of diabetic retinopathy. III. Prevalence and risk of diabeticretinopathy when age at diagnosis is 30 or more years. ArchOphthalmol. 1984;102:527–532.
Kohner E.M., Stratton I.M. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). // Diabetologia. 1999; 42 (9): 1107–1112.
Koss M.J., Naser H., Sener A., Ackermann H., Al-Sarireh F., Singh P. [et al.] Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. // Acta Ophthalmol. 2012; 90(6): 580-589.
Kumar B., Gupta S.K., Saxena R. et al. Current trends in the pharmacotherapy of diabetic retinopathy. // J. Postgrad. Med. . – 2012. – Vol. 58. – P. 132–139.
Kyryliuk ML, Malachkova NV, Komarovskaya IV. [Diabetic retinopathy and sex hormone-binding globulin: hypothesis or the real relationship?] Klinichna endokrynolohiia i endokrynna khyrurhiia. 2017;(3):65-72. [Russian].
Lechner J., O’Leary O.E., Stitt A.W. The pathology associated with diabetic retinopathy. // Vision Res. 2017; 139: 7-14.
Lee R., Wong T.Y., Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. // Eye Vis (Lond). 2015; 2: 17.
Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. // Int Ophthalmol Clin. 2009 Spring;49(2):35-52.
Liu Y. Risk factors of diabetic retinopathy and sight-threatening diabetic retinopathy: a cross-sectional study of 13473 patients with type 2 diabetes mellitus in mainland China / Y. Liu, J. Yang, L. Tao, H. Lv, X. Jiang, M. Zhang, X. Li // BMJ Open. – 2017. – Vol. 7, № 9. – Р. е016280.
Looker H.C., Nelson R.G., Chew E., Klein R., Klein B.E., Knowler W.C. [et al.] Genome-wide linkage analyses to identify Loci for diabetic retinopathy. // Diabetes. 2007; 56(4): 1160-1166.
Lopez-Plandolit S. Plasma Rich in Growth Factors as a Therapeutic Agent for Persistent Corneal Epithelial Defects. // Cornea. 2010; 29: 843-848.
Lu J. Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes / J. Lu, X. Ma, L. Zhang [et al.] // J Diabetes Investig. – 2019. – Vol. 10, № 3. – Р. 753-759.
Lustman P.J., Clouse R.E. Depression in diabetic patients: the relationship between mood and glycemic control // Journal of diabetes and its complications. 2005. Vol. 19 (2). P. 113-22.
Mahendra JV, et al. Plasma Fibrinogen in Type 2 Diabetic Patients with Metabolic Syndrome and its Relation with Ischemic Heart Disease (IHD) and Retinopathy. // J Clin Diagn Res. 2015 Jan;9(1):BC18-BC21.
Markan A., Agarwal A., Arora A., Bazgain K., Rana V., Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. // Ther Adv Ophthalmol. 2020; 12: 2515841420950513.
Massin P., Bandello F., Garweg J.G., Hansen L.L., Harding S.P., Larsen M. [et al.] Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. // Diabetes Care. 2010; 33(11): 2399-2405.
McGill J.I., Liakos G.M., Goulding N., Seal V. Normal tear protein profiles and age-related changes. // Br J Ophthalmol. 1984; 68(5): 316-320.
Misra S.L., Braatvedt G.D., Patel D.V. The impact of diabetes mellitus on the ocular surface: A review. // Clin Exp Ophthalmol. 2016; 44(4): 278-288.
Mitchell P, Smith W, Wang JJ, et al. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. // Ophthalmology. 1998;105:406–411.
Mohamed Q., Gillies M.C., Wong T.Y. Management of diabetic retinopathy: A systematic review. // JAMA. 2007; 298(8): 902-916.
Moll A., Wyka K., Młynarski W., Niwald A. Level of selected antibacterial tear proteins in children with diabetes type 1. // Klin. Oczna. 2011; 113(10-12): 336-340.
Moutray T., Evans J.R., Lois N., Armstrong D.J., Peto T., Azuara-Blanco A. Different lasers and techniques for proliferative diabetic retinopathy // Cochrane Database Syst Rev. 2018. Vol. 3(3). P. CD012314.
Muston D., Korobelnik J.F., Reason T. et al. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data // BMC Ophthalmol. 2018. Vol. 18 (1). P. 340.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. // Lancet. 2017; 389(10064): 37-55.
Nguyen-Khuong T., Everest-Dass A.V., Kautto L., Zhao Z., Willcox M.D.P., Packer N.H. Glycomic characterization of basal tears and changes with diabetes and diabetic retinopathy. // Glycobiology. 2015; 25(3): 269-283.
Opatrilova R., Kubatka P., Caprnda M., Busselberg D., Krasnik V., Vesely P. [et al.] Nitric oxide in the pathophysiology of retinopathy: Evidences from preclinical and clinical researches. Review Article. Acta Ophthalmol. 2018; 96(3): 222-231.
Osaadon P., Fagan X.J., Lifshitz T., Levy J. A review of antiVEGF agents for proliferative diabetic retinopathy. // Eye (Lond). 2014; 28(5): 510-520.
Palmer H., Giovannoni G., Stanford M. et al. Urinary neopterin in idiopathic retinal vasculitis // Br J Ophthalmol, 2001. № 85 (1). Р. 30-33.
Pan C.W. Prevalence, Awareness, and Risk Factors of Diabetic Retinopathy among Adults with Known Type 2 Diabetes Mellitus in an Urban Community in China / C.W. Pan, S. Wang, D.J. Qian, X. Cailian, E. Song // Ophthalmic Epidemiology. – 2017. – Vol. 24, № 3. – Р. 188-194.
Pankiv VI. Sympozium N162 "Tsukrovyi diabet: diahnostychni kryterii, etiolohiia i patohenez [Symposium No 162 "Diabetes mellitus: diagnostic criteria, etiology and pathogenesis"]. // Mizhnarodnyi Endokrynolohichnyi Zhurnal. 2013;8:53-64. [Ukrainian].
Quinto G.G., Campos M., Behrens A. Autologous serum for ocular surface diseases. // Arq. Bras.Oftalmol. 2008; 71: 1-6.
Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. // Diabetes. 1988;37(12):1595-1607.
Roden M., Shulman G.I. The integrative biology of type 2 diabetes. // Nature. 2019; 576(7785): 51-60.
Saari K.M., Aine E., Posz A., Klockars M. Lysozyme content of tears in normal subjects and in patients with external eye infections. // Graefes Arch Clin Exp Ophthalmol. 1983; 221(2): 86-88.
Sen D.K., Sarin G.S. Biological variations of lysozyme concentration in the tear fluids of healthy persons. // Br J Ophthalmol. 1986; 70(4): 246-248.
Serdyuk VN, Ishсhenko VA. [Morphometrial and biochemical clusters of metabolic syndrome in patients with type 2 diabetes mellitus at different stages of diabetic retinopathy]. Mizhnarodnyi endokrynolohichnyi zhurnal. 2016;(7):69-74. [Russian].
Shah K. Diabetic Retinopathy Awareness and Associations with Multiple Comorbidities: Insights from DIAMOND Study / K. Shah, A. Gandhi, S. Natarajan // Indian J Endocrinol Metab. – 2018. – Vol. 22, № 1. – P. 30-35.
Shaya F.T., Aljawadi M. Diabetic retinopathy. // Clin. Ophthalmol. 2007; 1(3): 259–65.
Shih K.C., Lam K.S., Tong L. A systematic review on the impact of diabetes mellitus on the ocular surface. // Nutr Diabetes. 2017; 7(3): e251.
Silva R.F., Trapé Á.A., Reia T.A., Lacchini R., Oliveira-Paula G.H., Pinheiro L.C. [et al.]. Association of endothelial nitric oxide synthase (eNOS) gene polymorphisms and physical fitness levels with plasma nitrite concentrations and arterial blood pressure values in older adults. // PLoS One. 2018; 13(10): e0206254.
Simó-Servat O., Hernández C., Simó R. Diabetic retinopathy in the context of patients with diabetes. // Ophthalmic Res. 2019; 62(4): 211-217.
Šimunović M., Paradžik M., Škrabić R., Unić I., Bućan K. Cataract as early ocular complication in children and adolescents with type 1 diabetes mellitus // Int. J. Endocrinol. 2018. Vol. 1. P. 1-6.
Sjølie A.K. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme / A.K. Sjølie [et al.] // Diabetic Medicine. – 2011. – V. 28, № 3. – Р. 345-351.
Skarbez K., Priestley Y., Hoepf M., Koevary S.B. Comprehensive review of the effects of diabetes on ocular health. // Expert Rev Ophthalmol. 2010; 5(4): 557-577.
Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. // Nature. 2007 Feb 22;445(7130):881-885.
Solomon S.D., Chew E., Duh E.J. [et al.] Diabetic Retinopathy: A Position Statement by the American Diabetes Association. // Diabetes Care. 2017;40(3):412-418.
Song B.J., Aiello L.P., Pasquale L.R. Presence and risk factors for glaucoma in patients with diabetes. // Curr Diab Rep. 2016; 16(12): 124.
Sun J.K., Miller J.W., Aiello L.P. Albert & Jakobiec’s Principles & Practice of Ophthalmology // 3rd Edition CHAPTER 135–Proliferative Diabetic Retinopathy. 2008. http://bookre.org/reader?file = 1375298.
Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. // Curr Med Chem. 2003 Aug;10(15):1329-1352.
Tang J. Early Assessment of the Risk Factors for Diabetic Retinopathy Can Reduce the Risk of Peripheral Arterial and Cardiovascular Diseases in Type 2 Diabetes / J. Tang, Т. Li, Р. Li, Y. Ma, M. Liu, Q. Shan, F. Guo, T. Zhou, Q. Wei // Ophthalmic Res. – 2018. – Vol. 59, № 4. – Р. 221-227.
Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factorsassociated with diabetic retinopathy in the Australian population. // Diabetes Care. 2003;26:1731–1737.
Tarr J.M, Kaul K., Chopra M., Kohner E.M., Chibber R. Pathophysiology of diabetic retinopathy // ISRN Ophthalmol. 2013; 2013: 343–560.
The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. February 18, 2015.
Tikellis G. Association between physical activity and retinal microvascular signs: the atherosclerosis risk in communities (ARIC) study / G.Tikellis [et al.] // Microcirculation. – 2010. – V.17, № 5. – Р. 381-393.
Varma R, Torres M, Peña F, et al. Prevalence of diabetic retinopathyin adult Latinos: the Los Angeles Latino eye study. // Ophthalmology.2004;111:1298–1306.
Vielma A.H., Retamal M.A., Schmachtenberg O. Nitric oxide signaling in the retina: What have we learned in two decades? // Brain Res. 2012; 1430: 1112-1125.
West SK, Klein R, Rodriguez J, et al. Proyecto VER. Diabetes and diabetic retinopathy in a Mexican-American population: ProyectoVER. // Diabetes Care. 2001;24:1204–1209.
Whitehead M., Wickremasinghe S., Osborne A., Van Wijngaarden P., Martin K.R. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies // Expert Opin Biol Ther. 2018. Vol. 18 (12). P. 1257-1270.
Wong TY, Hyman L. Population-based studies in ophthalmology. // Am J Ophthalmol. 2008; 146(5): 656-663.
Wu L., Fernandez-Loaiza P., Sauma J., Hernandez-Bogantes E., Masis M. Classification of diabetic retinopathy and diabetic macular edema. // World J Diabetes. 2013; 4(6): 290-294.
Wu Y., Tang L., Chen B. Oxidative stress: Implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxidative Medicine and Cellular Longevity. 2014; Vol. 2014: Article ID 752387: 1–12.